A new preclinical study suggests that combining next-generation CDK2 inhibitors with existing CDK4/6 therapies could overcome drug resistance in breast cancer, delivering durable tumour control across multiple subtypes.
A new study from researchers at The University of Texas MD Anderson Cancer Center has demonstrated that simultaneously targeting two key cell cycle regulators can produce durable anti-tumour effects across multiple breast cancer subtypes, including hard-to-treat forms of the disease. The study combined a selective cyclin-dependent kinase 2 (CDK2) inhibitor with existing cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which researchers believe could significantly improve outcomes for patients whose cancers no longer respond to standard therapies.